Author: admin

DelveInsight’s “Head and Neck Squamous Cell Carcinomas Patient Pool Analysis, Market Size and Market Forecast APAC – 2034″ report offers an in-depth understanding of the Head and Neck Squamous Cell Carcinomas, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinomas market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).

To Know in detail about the Head and Neck Squamous Cell Carcinomas market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Head and Neck Squamous Cell Carcinomas Market Forecast

Some of the key facts of the Head and Neck Squamous Cell Carcinomas Market Report:

• The APAC Head and Neck Squamous Cell Carcinomas market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In February 2025, Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for solid tumors, has announced the enrollment of the first patients in FORTIFI-HN01, a pivotal Phase 2/3 trial. This study evaluates ficerafusp alfa in combination with pembrolizumab as a first-line (1L) treatment for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).

• In January 2025, Rakuten Medical administered the first dose in its intercontinental Phase III clinical trial evaluating ASP-1929, a photoimmunotherapy treatment for recurrent head and neck squamous cell carcinoma (HNSCC). This multi-center, randomized, open-label study will assess the efficacy of the company’s antibody-dye conjugate, which combines the antibody drug cetuximab with MSD’s leading monoclonal antibody, Keytruda (pembrolizumab).

• In October 2024, MSD (Merck & Co.) has announced that its Phase III KEYNOTE-689 trial evaluating KEYTRUDA (pembrolizumab) for head and neck squamous cell carcinoma (HNSCC) successfully met its primary endpoint of event-free survival (EFS). The randomized, active-controlled, open-label study included 704 treatment-naïve patients with newly diagnosed stage III or IVA resected, locally advanced HNSCC (LA-HNSCC).

• In June 2024, Bicara Therapeutics has shared updated interim results from its ongoing Phase I/Ib clinical trial evaluating ficerafusp alfa for the treatment of human papillomavirus (HPV)-negative recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

• Key Head and Neck Squamous Cell Carcinomas Companies: M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer Institute, Inovio Pharmaceuticals, Hansoh BioMedical R&D Company, Gilead Sciences, Merck Sharp & Dohme LLC, Exelixis, Sichuan Baili Pharmaceutical Co., Ltd., AVEO Pharmaceuticals, Inc., Benitec Biopharma, Inc., BeiGene, ALX Oncology Inc., Queensland Health, Regeneron Pharmaceuticals, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• The Head and Neck Squamous Cell Carcinomas market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Head and Neck Squamous Cell Carcinomas pipeline products will significantly revolutionize the Head and Neck Squamous Cell Carcinomas market dynamics.

Head and Neck Squamous Cell Carcinomas Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) refers to a group of cancers that originate in the squamous cells lining the mucous membranes of the head and neck region. This includes the oral cavity, throat (pharynx), and voice box (larynx), among other areas. Squamous cells are flat, thin cells that make up the epithelium, the outer layer of the skin and the lining of various organs.

Get a Free sample for the Head and Neck Squamous Cell Carcinomas Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinomas-hnsccs-market-size-and-forecast

Head and Neck Squamous Cell Carcinomas Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2020-2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Head and Neck Squamous Cell Carcinomas Epidemiology Segmentation:

The Head and Neck Squamous Cell Carcinomas market report proffers epidemiological analysis for the study period 2020-2034 in the APAC region is segmented into:

• Total Prevalence of Head and Neck Squamous Cell Carcinomas

• Prevalent Cases of Head and Neck Squamous Cell Carcinomas by severity

• Gender-specific Prevalence of Head and Neck Squamous Cell Carcinomas

• Diagnosed Cases of Episodic and Chronic Head and Neck Squamous Cell Carcinomas

Download the report to understand which factors are driving Head and Neck Squamous Cell Carcinomas epidemiology trends @ Head and Neck Squamous Cell Carcinomas Epidemiology Forecast

Head and Neck Squamous Cell Carcinomas Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Head and Neck Squamous Cell Carcinomas market or expected to get launched during the study period. The analysis covers Head and Neck Squamous Cell Carcinomas market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Head and Neck Squamous Cell Carcinomas Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Head and Neck Squamous Cell Carcinomas Therapies and Key Companies

• Pembrolizumab: M.D. Anderson Cancer Center

• Nivolumab: Sidney Kimmel

• Durvalumab: Centre hospitalier de

• Taxotere: Dana-Farber Cancer Institute

• CELLECTRA™-5P: Inovio Pharmaceuticals

• HS-20093: Hansoh BioMedical R&D Company

• Magrolimab: Gilead Sciences

• Lenvatinib: Merck Sharp & Dohme LLC

• Zanzalintinib: Exelixis

• BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

• Ficlatuzumab: AVEO Pharmaceuticals, Inc.

• BB-401: Benitec Biopharma, Inc.

• Tislelizumab: BeiGene

• SI-B001: Sichuan Baili Pharmaceutical Co., Ltd.

• Evorpacept: ALX Oncology Inc.

• Pembrolizumab: Queensland Health

• Evorpacept: ALX Oncology Inc.

• CMP-001: Regeneron Pharmaceuticals

Discover more about therapies set to grab major Head and Neck Squamous Cell Carcinomas market share @ Head and Neck Squamous Cell Carcinomas Treatment Landscape

Scope of the Head and Neck Squamous Cell Carcinomas Market Report

• Study Period: 2020-2034

• Coverage: APAC (India, China, South Korea, Taiwan, and Australia)

• Key Head and Neck Squamous Cell Carcinomas Companies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Head and Neck Squamous Cell Carcinomas Therapeutic Assessment: Head and Neck Squamous Cell Carcinomas current marketed and Head and Neck Squamous Cell Carcinomas emerging therapies

• Head and Neck Squamous Cell Carcinomas Market Dynamics: Head and Neck Squamous Cell Carcinomas market drivers and Head and Neck Squamous Cell Carcinomas market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Head and Neck Squamous Cell Carcinomas Unmet Needs, KOL’s views, Analyst’s views, Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement

To know more about Head and Neck Squamous Cell Carcinomas companies working in the treatment market, visit @ Head and Neck Squamous Cell Carcinomas Clinical Trials and Therapeutic Assessment

Table of Contents

1. Head and Neck Squamous Cell Carcinomas Market Report Introduction

2. Executive Summary for Head and Neck Squamous Cell Carcinomas

3. SWOT analysis of Head and Neck Squamous Cell Carcinomas

4. Patient Share (%) Overview at a Glance

5. Head and Neck Squamous Cell Carcinomas Market Overview at a Glance

6. Head and Neck Squamous Cell Carcinomas Disease Background and Overview

7. Head and Neck Squamous Cell Carcinomas Epidemiology and Patient Population

8. Country-Specific Patient Population of Head and Neck Squamous Cell Carcinomas

9. Head and Neck Squamous Cell Carcinomas Current Treatment and Medical Practices

10. Head and Neck Squamous Cell Carcinomas Unmet Needs

11. Head and Neck Squamous Cell Carcinomas Emerging Therapies

12. Head and Neck Squamous Cell Carcinomas Market Outlook

13. Country-Wise Head and Neck Squamous Cell Carcinomas Market Analysis (2020-2034)

14. Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement of Therapies

15. Head and Neck Squamous Cell Carcinomas Market Drivers

16. Head and Neck Squamous Cell Carcinomas Market Barriers

17. Head and Neck Squamous Cell Carcinomas Appendix

18. Head and Neck Squamous Cell Carcinomas Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Head and Neck Squamous Cell Carcinomas Market to Expand Significantly by 2034 Across APAC Region, States DelveInsight Reports | M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de

The Soft Tissue Sarcoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Soft Tissue Sarcoma pipeline products will significantly revolutionize the Soft Tissue Sarcoma market dynamics.

DelveInsight’s “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Soft Tissue Sarcoma, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Soft Tissue Sarcoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Soft Tissue Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Soft Tissue Sarcoma Market Forecast

Some of the key facts of the Soft Tissue Sarcoma Market Report:

• The Soft Tissue Sarcoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In January 2025, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company specializing in targeted immunotherapeutic drugs, has announced an expansion of its Phase 1 SB101 clinical trial for SON-1010 (IL12-FHAB) in adults with advanced solid tumors. Following the successful completion of monotherapy dose escalation, the study will now include a new cohort to assess SON-1010 in combination with trabectedin (Yondelis®). This expansion aims to evaluate the immune-oncology effects of SON-1010 at the maximum tolerated dose (MTD) of 1200 ng/kg alongside trabectedin, a chemotherapy drug approved for certain advanced soft-tissue sarcomas (STS), with the goal of enhancing local immune response in the tumor microenvironment (TME).

• In October 2024, Adcendo’s antibody-drug conjugate (ADC) candidate has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) and is set to advance into a Phase I/II clinical trial. The Danish immuno-oncology company will initiate the ADCElerate-01 trial, a multi-center, first-in-human Phase I/II study designed to assess the safety and efficacy of ADCE-D01 as a monotherapy in patients with metastatic and unresectable soft tissue sarcoma (STS). ADCE-D01 specifically targets the endocytic receptor uPARAP (Endo180).

• In July 2024, Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage clinical biotechnology company specializing in novel immune-based intratumoral cancer therapies, has announced that the first U.S. patient has been dosed in its Phase 3 trial for metastatic sarcoma (NCT06263231). The study aims to evaluate the efficacy of INT230-6 as a monotherapy compared to the investigator’s choice of three standard systemic chemotherapy options for second- or third-line treatment of metastatic, recurrent, or inoperable soft tissue sarcomas (STS). This superiority trial seeks to both directly eliminate tumors and enhance immune system recognition of cancer cells.

• There were around 42 thousand incident cases of Soft Tissue Sarcoma in the 7MM, in 2021.

• According to Wiltink et al., Soft tissue Sarcoma (STS) are a diverse group of rare tumors of mesenchymal origin with different clinical, histologic and molecular characteristics

• American Association for Thoracic Surgery (AATS) (n.d.), stated that up to 50%of patients with soft tissue sarcoma (STS) develop lung metastasis. Also Nakamura et al. (2021), in a study mentioned that lung metastasis from Soft Tissue Sarcoma (STS) occurs in 20–50% of Soft Tissue Sarcoma (STS) patients

• Key Soft Tissue Sarcoma Companies: Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others

• Key Soft Tissue Sarcoma Therapies: Liposomal Annamycin, and others

Soft Tissue Sarcoma Overview

The term soft tissue sarcoma (STS) refers to malignant soft-tissue tumors that may arise anywhere on the body and may consist of a variety of histological subtypes (including lipo Sarcoma, rhabdomyo Sarcoma, synovial Sarcoma, leiomyo Sarcoma, and fibro Sarcoma). As sarcoma may arise virtually anywhere, but the extremity is the most common primary site. Despite progress in multimodality treatment, a large number of patients die each year of soft tissue sarcoma.

Get a Free sample for the Soft Tissue Sarcoma Market Report:

https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market

Soft Tissue Sarcoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Soft Tissue Sarcoma Epidemiology Segmentation:

The Soft Tissue Sarcoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Soft Tissue Sarcoma

• Prevalent Cases of Soft Tissue Sarcoma by severity

• Gender-specific Prevalence of Soft Tissue Sarcoma

• Diagnosed Cases of Episodic and Chronic Soft Tissue Sarcoma

Download the report to understand which factors are driving Soft Tissue Sarcoma epidemiology trends @ Soft Tissue Sarcoma Epidemiological Insights

Soft Tissue Sarcoma Market

The dynamics of the Soft Tissue Sarcoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

“The current pipeline of Soft Tissue Sarcoma is not very rich. A limited number of therapeutic approaches are being evaluated for the patients. As some molecule probably will enter in market in upcoming years, the market is supposed to experience immense growth in future”

Soft Tissue Sarcoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Soft Tissue Sarcoma market or expected to get launched during the study period. The analysis covers Soft Tissue Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Soft Tissue Sarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Soft Tissue Sarcoma Therapies and Key Companies

• Liposomal Annamycin: Moleculin Biotech, Inc.

To know more about Soft Tissue Sarcoma treatment, visit @ Soft Tissue Sarcoma Medications

Scope of the Soft Tissue Sarcoma Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Soft Tissue Sarcoma Companies: Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others

• Key Soft Tissue Sarcoma Therapies: Liposomal Annamycin, and others

• Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies

• Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Soft Tissue Sarcoma Unmet Needs, KOL’s views, Analyst’s views, Soft Tissue Sarcoma Market Access and Reimbursement

Discover more about therapies set to grab major Soft Tissue Sarcoma market share @ Soft Tissue Sarcoma Treatment Landscape

Table of Contents

1. Soft Tissue Sarcoma Market Report Introduction

2. Executive Summary for Soft Tissue Sarcoma

3. SWOT analysis of Soft Tissue Sarcoma

4. Soft Tissue Sarcoma Patient Share (%) Overview at a Glance

5. Soft Tissue Sarcoma Market Overview at a Glance

6. Soft Tissue Sarcoma Disease Background and Overview

7. Soft Tissue Sarcoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Soft Tissue Sarcoma

9. Soft Tissue Sarcoma Current Treatment and Medical Practices

10. Soft Tissue Sarcoma Unmet Needs

11. Soft Tissue Sarcoma Emerging Therapies

12. Soft Tissue Sarcoma Market Outlook

13. Country-Wise Soft Tissue Sarcoma Market Analysis (2019–2032)

14. Soft Tissue Sarcoma Market Access and Reimbursement of Therapies

15. Soft Tissue Sarcoma Market Drivers

16. Soft Tissue Sarcoma Market Barriers

17. Soft Tissue Sarcoma Appendix

18. Soft Tissue Sarcoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Soft Tissue Sarcoma Market on Track for Major Expansion by 2032, According to DelveInsight | Moleculin Biotech

DelveInsight’s latest report, “Merkel Cell Carcinoma Market Insight, Epidemiology, and Market Forecast,” combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the Merkel Cell Carcinoma (MCC) market in the 7MM which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan is expected to grow at a CAGR of 8.7% from USD 411 million between 2023 to 2034

Among the 7MM, the US market represented 44% of the total market size in 2023. Other major markets, EU4 and the UK, accounted for approximately 54%. Among the EU4 and the UK, Germany held the largest Merkel Cell Carcinoma market share, followed by France.

Download the report to understand which factors are driving the Merkel Cell Carcinoma therapeutic market @ Merkel Cell Carcinoma Market Trends.

The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by Total Merkel Cell Carcinoma Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM.

According to DelveInsight’s analysis, there were approximately 9000 incident cases of MCC in the 7MM. Among them, the United States accounted for nearly 37% of the cases in 2023. Furthermore, in the EU4 and the UK, approximately 80% of the total reported cases are associated with MCPyV, while 20% are linked to UV damage, indicating that MCPyV is the primary causative factor.

Discover evolving trends in Merkel Cell Carcinoma patient pool forecasts @ Merkel Cell Carcinoma Epidemiology Analysis

The Delveinsight report also discusses current diagnosis and treatment strategies for Merkel Cell Carcinoma. Existing drugs for MCC treatment include KEYTRUDA (Merck), ZYNYZ (Incyte Corporation/MacroGenics), and BAVENCIO (Merck KGaA).

The treatment depends on the disease stage and individual factors, primarily involving surgery as the first-line therapy, often combined with radiation or chemotherapy. Chemotherapy, once a key treatment for advanced Merkel Cell Carcinoma, now plays a reduced role due to limited long-term effectiveness. Cytotoxic chemotherapy, while it has been effective for metastatic MCC, often leads to significant side effects by affecting normal cells.

DelveInsight’s analysis reveals that several companies are launching clinical trials to investigate new MCC treatment options or to improve existing ones. The Merkel Cell Carcinoma clinical development pipeline includes drugs such as IFx-2.0 (TuHURA Biosciences), NIDLEGY (Philogen), MCLA 145 (Merus N.V.), ITI 3000 (Immunomic Therapeutics), PH 762 (Phio Pharmaceuticals/AgonOx), and KT 253 (Kymera Therapeutics), among others.

Unlock which emerging Merkel Cell Carcinoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Merkel Cell Carcinoma Market Insights.

In January 2025, 225Ac-SSO110, a somatostatin receptor 2 (SST2) antagonist for targeted radionuclide cancer treatments of MCC developed by Ariceum Therapeutics, received clearance for a Phase 1/2 trial (SANTANA-225) and is expected to begin enrolling patients in the first quarter of 2025. Another pipeline drug, IFx-2.0 (developed by TuHURA Biosciences), is also set for phase III trial with KEYTRUDA for advanced MCC in 2025. These developments highlight the momentum in the MCC treatment landscape.

MCC presents significant challenges, especially in diagnosis, due to its rarity, unclear origin, and similarity to other skin lesions. DelveInsight’s leading oncology consultant commented, “As MCCs are frequently misdiagnosed, biomarkers are needed to improve their detection to prompt biopsy to confirm diagnosis by histology and immunohistochemistry, respectively.” This highlights the potential of more precise and sensitive emerging diagnostic methods to revolutionize Merkel Cell Carcinoma treatment, driving market growth.

Table of Contents

Related Reports

Merkel Cell Carcinoma Pipeline Insight

Merkel Cell Carcinoma Pipeline Insight provides comprehensive insights about the Merkel Cell Carcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Merkel Cell Carcinoma companies, including ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos therapeutics, Incyte corporation, Amgen, BioInvent International AB, SOTIO Biotech, Xencor, Exicure, Checkmate Pharmaceuticals, Takeda, Genocea Biosciences, NeoImmuneTech, and Sensei Biotherapeutics, among others.

About DelveInsight

DelveInsight is a leading business Healthcare consultancy and market research firm specializing in life sciences. It assists pharmaceutical companies by offering comprehensive, end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% During the Study Period (2020-2034) | DelveInsight

DelveInsight’s “CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma, historical and forecasted epidemiology as well as the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma, offering comprehensive insights into the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma revenue trends, prevalence, and treatment landscape. The report delves into key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CAR T-Cell Therapy for Non-Hodgkin’s lymphoma therapies. Additionally, we cover the landscape of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma space.

To Know in detail about the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Forecast

Some of the key facts of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report:

• The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In November 2024, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company developing next-generation CAR T-cell therapies for patients with solid tumors or hematologic cancers, announced that an abstract featuring initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented by Dr. Sarah M. Larson, Associate Professor, Department of Medicine and Medical Director of the Immune Effector Cell Therapy Program at the David Geffen School of Medicine at UCLA, during the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA, from December 7 to 10, 2024. IMPT-314 is a dual-targeting CD19/CD20 CAR T-cell therapy being developed for patients with aggressive B-cell non-Hodgkin’s lymphoma.

• In May 2024, Verismo Therapeutics obtained FDA IND clearance for SynKIR-310 in relapsed/refractory B-cell NHL.

• In March 2024, Bristol Myers Squibb announced that the US FDA has approved BREYANZI as the first and only CAR T-cell therapy for adults with relapsed/refractory CLL or SLL.

• Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Companies: Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, BMS, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others

• Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies: Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others

• The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CAR T-Cell Therapy for Non-Hodgkin’s lymphoma pipeline products will significantly revolutionize the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market dynamics.

• According to DelveInsight’s estimates, the total number of NHL cases eligible for CAR-T therapy in the 7MM was approximately 125,900 in 2023.

• DLBCL is the most common subtype of non-Hodgkin lymphoma in the EU4 and UK, with around 32,400 cases reported in 2023.

• In 2023, Japan reported around 23,700 incident cases of NHL across selected subtypes.

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Overview

Chimeric Antigen Receptor (CAR) T-cell therapy is an innovative treatment for certain types of Non-Hodgkin’s lymphoma. It involves modifying a patient’s own T-cells (a type of immune cell) to express a receptor that targets and kills cancerous B-cells, which are typically present in NHL. These modified T-cells are then infused back into the patient, where they recognize and destroy lymphoma cells. CAR T-cell therapy has shown promising results for patients with relapsed or refractory NHL, particularly for aggressive forms of the disease. It is considered a breakthrough in cancer immunotherapy due to its ability to harness the body’s immune system for targeted treatment.

Get a Free sample for the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology Segmentation:

The CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma

• Prevalent Cases of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma by severity

• Gender-specific Prevalence of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma

• Diagnosed Cases of Episodic and Chronic CAR T-Cell Therapy for Non-Hodgkin’s lymphoma

Download the report to understand which factors are driving CAR T-Cell Therapy for Non-Hodgkin’s lymphoma epidemiology trends @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology Forecast

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market or expected to get launched during the study period. The analysis covers CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies and Key Companies

• Human CD19Targeted T Cells Injection: Hrain Biotechnology

• Mosunetuzumab: Lazaros Lekakis

• IM19 CAR-T Cells: Beijing Immunochina Medical Science

• lisocabtagene maraleucel: Juno Therapeutics

• YESCARTA: Gilead Sciences

• KYMRIAH: Novartis

• BREYANZI: BMS

• Cemacabtagene ansegedleucel: Allogene Therapeutics

• Rapcabtagene autoleucel (YTB323): Novartis

• Zamtocabtagene autoleucel: Miltenyi Biomedicine

• AUTO4: Autolus Therapeutics

• CD30.CAR-T: Tessa Therapeutics

Discover more about therapies set to grab major CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market share @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Treatment Landscape

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Drivers

• Advancements in Immunotherapy

• Efficacy in Relapsed/Refractory NHL

• FDA Approvals

• Increasing Incidence of NHL

• Ongoing Clinical Trials and Research

• Positive Patient Outcomes

CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Barriers

• High Treatment Costs

• Limited Treatment Accessibility

• Complex Manufacturing Process

• Potential Side Effects

• Reimbursement Challenges

• Long-Term Efficacy and Safety Uncertainty

Scope of the CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Companies: Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science, Juno Therapeutics, Gilead Sciences, Novartis, BMS, Allogene Therapeutics, Miltenyi Biomedicine, Autolus Therapeutics, Tessa Therapeutics, and others

• Key CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapies: Human CD19Targeted T Cells Injection, Mosunetuzumab, IM19 CAR-T Cells, lisocabtagene maraleucel, YESCARTA, KYMRIAH, BREYANZI, Cemacabtagene ansegedleucel, Rapcabtagene autoleucel (YTB323), Zamtocabtagene autoleucel, AUTO4, CD30.CAR-T, and others

• CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Therapeutic Assessment: CAR T-Cell Therapy for Non-Hodgkin’s lymphoma current marketed and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma emerging therapies

• CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Dynamics: CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market drivers and CAR T-Cell Therapy for Non-Hodgkin’s lymphoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Unmet Needs, KOL’s views, Analyst’s views, CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Access and Reimbursement

To know more about CAR T-Cell Therapy for Non-Hodgkin’s lymphoma companies working in the treatment market, visit @ CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Report Introduction

2. Executive Summary for CAR T-Cell Therapy for Non-Hodgkin’s lymphoma

3. SWOT analysis of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma

4. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Patient Share (%) Overview at a Glance

5. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Overview at a Glance

6. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Disease Background and Overview

7. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of CAR T-Cell Therapy for Non-Hodgkin’s lymphoma

9. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Current Treatment and Medical Practices

10. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Unmet Needs

11. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Emerging Therapies

12. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Outlook

13. Country-Wise CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Analysis (2020–2034)

14. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Access and Reimbursement of Therapies

15. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Drivers

16. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Barriers

17. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Appendix

18. CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Hrain Biotechnology, Lazaros Lekakis, Beijing Immunochina Medical Science